Physician profile
Pratik D Modi
NPI 1992133433
$2,434.98
in general payments reported to CMS, 2019-2025
33 companies · $307 in 2025
The $307 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $830 · 2022: $38.87 · 2023: $215 · 2024: $1,044 · 2025: $307.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,566.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,566.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $320.44 | 2023-2025 | Ingrezza |
| Abbvie INC. | $259.98 | 2021-2024 | |
| Otsuka America Pharmaceutical, INC. | $171.05 | 2021-2024 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $130.22 | 2024-2025 | Austedo Xr, Austedo Xr |
| Ucb, INC. | $127.36 | 2021-2025 | Zilbrysq, Rystiggo |
| Acadia Pharmaceuticals INC | $127.02 | 2023-2024 | Nuplazid |
| Lilly USA, LLC | $122.50 | 2021-2025 | Kisunla, Amyvid |
| Alexion Pharmaceuticals, INC. | $119.76 | 2024 | Ultomiris |
| Eisai INC. | $95.63 | 2023-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $81.84 | 2021-2025 | Hyqvia |
| Horizon Therapeutics Plc | $76.11 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $75.93 | 2021 | |
| Acorda Therapeutics, INC | $66.78 | 2023-2024 | Inbrija |
| Glaxosmithkline, LLC. | $66.52 | 2021 | |
| Sunovion Pharmaceuticals INC. | $63.91 | 2021 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amneal Pharmaceuticals LLC | $63.60 | 2024-2025 | Crexont, Rytary |
| Kyowa Kirin, INC. | $51.02 | 2024 | Nourianz |
| Astrazeneca Pharmaceuticals LP | $45.32 | 2021-2025 | Wainua |
| Merz Pharmaceuticals, LLC | $44.52 | 2024-2025 | Xeomin, Inbrija |
| Amarin Pharma, INC. | $37.10 | 2021 | |
| Cmp Pharma, INC. | $35.55 | 2021 | |
| Novo Nordisk INC | $33.64 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $23.41 | 2021 | |
| Redhill Biopharma INC. | $23.32 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $22.46 | 2022 | |
| Lundbeck LLC | $22.33 | 2024 | Rexulti |
| Merck Sharp & Dohme LLC | $21.64 | 2021 | |
| Kedrion Biopharma, INC. | $21.00 | 2024 | Rhogam Ultra-Filtered Plus, Albuked, Gammaked |
| Scilex Pharmaceuticals INC. | $20.95 | 2021 | |
| Vivus LLC | $19.76 | 2021 | |
| Neurelis, INC. | $14.84 | 2024 | Valtoco |
| Janssen Biotech, INC. | $14.74 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.73 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pratik Modi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.